Compare BBVA & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BBVA | VRTX |
|---|---|---|
| Founded | 1857 | 1989 |
| Country | Spain | United States |
| Employees | 126877 | N/A |
| Industry | Commercial Banks | EDP Services |
| Sector | Finance | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 134.0B | 124.7B |
| IPO Year | N/A | 2006 |
| Metric | BBVA | VRTX |
|---|---|---|
| Price | $25.66 | $474.70 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 29 |
| Target Price | N/A | ★ $539.69 |
| AVG Volume (30 Days) | 1.4M | ★ 1.6M |
| Earning Date | 04-30-2026 | 05-04-2026 |
| Dividend Yield | ★ 4.08% | N/A |
| EPS Growth | N/A | ★ 836.54 |
| EPS | N/A | ★ 4.02 |
| Revenue | N/A | ★ $2,488,652,000.00 |
| Revenue This Year | $29.69 | $10.79 |
| Revenue Next Year | $5.39 | $10.47 |
| P/E Ratio | ★ $11.24 | $119.63 |
| Revenue Growth | N/A | ★ 46.20 |
| 52 Week Low | $14.63 | $362.50 |
| 52 Week High | $26.40 | $533.67 |
| Indicator | BBVA | VRTX |
|---|---|---|
| Relative Strength Index (RSI) | 62.12 | 47.96 |
| Support Level | $23.10 | $422.12 |
| Resistance Level | $26.25 | $486.26 |
| Average True Range (ATR) | 0.37 | 16.00 |
| MACD | -0.01 | -3.73 |
| Stochastic Oscillator | 69.63 | 7.10 |
Despite its Spanish origins, Banco Bilbao Vizcaya Argentaria generates only around one-fourth of its profits in Spain. We expect that on a normalized basis, BBVA's market-leading Mexican bank should contribute half of its earnings, while its Turkish operation should account for another 15%. The balance of BBVA's earnings comes from smaller operations in South America. BBVA is overwhelmingly a retail and commercial bank, with corporate and investment banking forming a minor part of the overall business. BBVA also offers insurance and investment products through its banking networks.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.